Montai Health is a company harnessing nature's power through digital technology to treat and prevent chronic diseases. They are pioneering the development of AnthromoleculeTM medications, derived from a privileged class of compounds with a history of safe human use. Their goal is to improve health outcomes for as many people as possible by creating the world's first Anthromolecule Bioactivity Atlas.

Montai Health is unlocking the power of nature with its pioneering AI-powered CONECTA™ platform to develop Anthromolecule™ medicines that will treat and preempt chronic diseases to improve health outcomes for the 2 billion people worldwide living with these diseases. Anthromolecule chemistry has co-evolved with humans through long term chronic consumption in foods, herbs, and traditional medicines. It offers a privileged starting point for developing breakthrough small-molecule medicines to address chronic diseases. Montai's CONECTA platform is powered by hyper-efficient, generalizable ML and the aggregation of Anthromolecule chemistry at industry first scale to predictably discover precision-matched, human-qualified chemistry that potently and safely engages validated biological pathways. Montai is rapidly advancing a pipeline of first-in-class or best-in-class small-molecule assets against multiple powerful, validated biological pathways in inflammation and autoimmune. Montai was founded in Flagship Labs in 2019. For more information, please visit www.montai.com. 

COM:MONTAI

Montai Health

Analysis Not Available